Lars Kjellström1, Herdis Molinder, Lars Agréus, Henry Nyhlin, Nicholas J Talley, Anna Andreasson. 1. aCentre for Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge bDepartment of Medicine, Karolinska Institutet, Solna cCentre for Gastrointestinal Disease, Sabbatsberg Hospital dStress Research Institute, Stockholm University, Stockholm, Sweden eFaculty of Health, University of Newcastle, Callaghan, New South Wales, Australia.
Abstract
OBJECTIVE: To analyse the epidemiology of irritable bowel syndrome (IBS) symptoms in a random sample of the general population and in a subsample consenting to a colonoscopy, and to what extent this introduces symptom selection bias. MATERIALS AND METHODS: Overall, 3347 randomly selected Swedish adults aged 18-70 years were mailed the validated Abdominal Symptom Questionnaire (ASQ). Responders (n=2293; 68.5%) were contacted by phone, and 745 consented to a colonoscopy. All nonresponders were contacted by phone; 265 were reached and asked seven key ASQ questions. Colonoscopy participants also completed the Rome II Modular Questionnaire. RESULTS: The prevalence of IBS on the basis of the mailed ASQ (troublesome abdominal pain and bowel disturbance in the past 3 months) was 26.2% [95% confidence interval (CI): 24.4-28.0] among the ASQ responders and 36.6% (95% CI: 33.2-40.1) among the colonoscopy participants (P<0.001). Nonresponders had a lower prevalence of IBS (15.8%; 95% CI: 11.4-20.3, P<0.001) than ASQ responders. Colonoscopy participants were slightly older than noncolonoscoped participants completing the ASQ (P<0.001), but men and women were equally represented and no significant socioeconomic differences were identified. The prevalence of IBS was 14.8% (95% CI: 12.2-17.5) on the basis of the Rome II Modular Questionnaire in colonoscopy participants and 14.5% (95% CI: 11.9-17.2) when visible inflammatory disease was excluded. Of the colonoscopy participants, 31.9% (95% CI: 28.5-35.3) were symptom free. CONCLUSION: IBS symptoms are common and rarely explained by visible inflammatory disease or cancer. There was a modest selection bias by IBS in participants accepting a screening colonoscopy, but still, one-third were symptom free. Thus, conclusions for the general population can be made from findings in the study cohort.
OBJECTIVE: To analyse the epidemiology of irritable bowel syndrome (IBS) symptoms in a random sample of the general population and in a subsample consenting to a colonoscopy, and to what extent this introduces symptom selection bias. MATERIALS AND METHODS: Overall, 3347 randomly selected Swedish adults aged 18-70 years were mailed the validated Abdominal Symptom Questionnaire (ASQ). Responders (n=2293; 68.5%) were contacted by phone, and 745 consented to a colonoscopy. All nonresponders were contacted by phone; 265 were reached and asked seven key ASQ questions. Colonoscopy participants also completed the Rome II Modular Questionnaire. RESULTS: The prevalence of IBS on the basis of the mailed ASQ (troublesome abdominal pain and bowel disturbance in the past 3 months) was 26.2% [95% confidence interval (CI): 24.4-28.0] among the ASQ responders and 36.6% (95% CI: 33.2-40.1) among the colonoscopy participants (P<0.001). Nonresponders had a lower prevalence of IBS (15.8%; 95% CI: 11.4-20.3, P<0.001) than ASQ responders. Colonoscopy participants were slightly older than noncolonoscoped participants completing the ASQ (P<0.001), but men and women were equally represented and no significant socioeconomic differences were identified. The prevalence of IBS was 14.8% (95% CI: 12.2-17.5) on the basis of the Rome II Modular Questionnaire in colonoscopy participants and 14.5% (95% CI: 11.9-17.2) when visible inflammatory disease was excluded. Of the colonoscopy participants, 31.9% (95% CI: 28.5-35.3) were symptom free. CONCLUSION:IBS symptoms are common and rarely explained by visible inflammatory disease or cancer. There was a modest selection bias by IBS in participants accepting a screening colonoscopy, but still, one-third were symptom free. Thus, conclusions for the general population can be made from findings in the study cohort.
Authors: Brjánn Ljótsson; Michael Jones; Nicholas J Talley; Lars Kjellström; Lars Agréus; Anna Andreasson Journal: United European Gastroenterol J Date: 2020-01-14 Impact factor: 4.623
Authors: Anne F Peery; Temitope O Keku; Cassandra Addamo; Amber N McCoy; Christopher F Martin; Joseph A Galanko; Robert S Sandler Journal: Clin Gastroenterol Hepatol Date: 2017-06-08 Impact factor: 11.382
Authors: Kyle Staller; Ola Olén; Jonas Söderling; Bjorn Roelstraete; Hans Törnblom; Hamed Khalili; Mingyang Song; Jonas F Ludvigsson Journal: Eur J Intern Med Date: 2021-08-20 Impact factor: 4.487
Authors: Herdis Molinder; Lars Agréus; Lars Kjellström; Susanna Walter; Nicholas J Talley; Anna Andreasson; Henry Nyhlin Journal: Ups J Med Sci Date: 2015 Impact factor: 2.384
Authors: Maria Henström; Lena Diekmann; Ferdinando Bonfiglio; Fatemeh Hadizadeh; Eva-Maria Kuech; Maren von Köckritz-Blickwede; Louise B Thingholm; Tenghao Zheng; Ghazaleh Assadi; Claudia Dierks; Martin Heine; Ute Philipp; Ottmar Distl; Mary E Money; Meriem Belheouane; Femke-Anouska Heinsen; Joseph Rafter; Gerardo Nardone; Rosario Cuomo; Paolo Usai-Satta; Francesca Galeazzi; Matteo Neri; Susanna Walter; Magnus Simrén; Pontus Karling; Bodil Ohlsson; Peter T Schmidt; Greger Lindberg; Aldona Dlugosz; Lars Agreus; Anna Andreasson; Emeran Mayer; John F Baines; Lars Engstrand; Piero Portincasa; Massimo Bellini; Vincenzo Stanghellini; Giovanni Barbara; Lin Chang; Michael Camilleri; Andre Franke; Hassan Y Naim; Mauro D'Amato Journal: Gut Date: 2016-11-21 Impact factor: 23.059
Authors: Fatemeh Hadizadeh; Ferdinando Bonfiglio; Meriem Belheouane; Marie Vallier; Sascha Sauer; Corinna Bang; Luis Bujanda; Anna Andreasson; Lars Agreus; Lars Engstrand; Nicholas J Talley; Joseph Rafter; John F Baines; Susanna Walter; Andre Franke; Mauro D'Amato Journal: Gut Date: 2017-08-01 Impact factor: 23.059